Bandhan Focused Fund
The scheme aims to generate capital appreciation by investing in a concentrated portfolio of equity & equity related instruments of upto 30 stocks.
Growthvine rating: 2/5 — ranked #19 of 28 in category.
Fund basics
| Category | Equity: Focused |
|---|
| NAV | ₹88.97 (as of 2026-08-21) |
|---|
| AUM | ₹2,086 Cr |
|---|
| Expense ratio | 1.75% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Kirthi Jain |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 365 days |
|---|
Performance & risk
| 5-year annualised return | 12.15% |
|---|
| Sharpe ratio | 0.53 |
|---|
| Standard deviation | 16.59% |
|---|
| Max drawdown | -39.22% |
|---|
| Alpha | 2.22 |
|---|
| Beta | 0.99 |
|---|
Over 5 years, captured 98.1% of Nifty 500's upside and 96.2% of its downside.
Market cap allocation
| Large cap | 41.8% |
|---|
| Mid cap | 14.2% |
|---|
| Small cap | 44.0% |
|---|
Concentration
| Top 5 holdings | 33.2% |
|---|
| Top 10 holdings | 55.6% |
|---|
| Total holdings | 27 |
|---|
| Index overlap | 26.6% |
|---|
| Active share | 73.4% |
|---|
Top holdings
- LT Foods Limited — 8.3%
- Prestige Estates Projects Limited — 6.7%
- HDFC Bank Ltd. — 6.6%
- CHOLAMANDALAM FINANCIAL HOLDINGS LIMITED — 6.0%
- Power Finance Corporation Ltd — 5.6%
- JUBILANT PHARMOVA LIMITED — 5.4%
- ICICI Bank Ltd. — 4.9%
- Glenmark Pharmaceuticals ltd — 4.9%
- Tilaknagar Industries Ltd — 3.7%
- Triparty Repo TRP_030826 — 3.7%
Top sectors
- Banking & Financial — 22.9%
- Retail — 15.1%
- Pharma & Biotech — 12.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 1.3% | Q3 | #15 of 28 |
| 2025 | -1.6% | Q4 (Bottom) | #24 of 28 |
| 2024 | 30.3% | Q1 (Top) | #2 of 27 |
| 2023 | 31.3% | Q1 (Top) | #4 of 25 |
| 2022 | -5.0% | Q4 (Bottom) | #18 of 22 |